Those familiar with the asbestos-caused cancer mesothelioma are well aware the disease takes decades to develop and by the time it’s recognized, it’s too late for recovery. When symptoms finally develop and mesothelioma is diagnosed, its victims often survive less than one year.
In 2008, Japanese researchers released a study about a protein produced by certain cancer cells and it’s ability to mark mesothelioma tumors. Six years later, the same scientists discovered the biomarker may serve as a warning tool for those at risk for mesothelioma.
In 2007, the group selected 40,000 participants who worked with asbestos earlier in life and collected annual blood samples to monitor for the protein. From that research, they selected 62 subjects with the highest chances of developing the cancer. Of the 62 most likely, two have already been diagnosed and the other 60 are being carefully checked.
Depending on further results, monitoring this protein may help at-risk people determine if they will develop mesothelioma. A quicker diagnosis may save, or at least prolong, many lives until a cure is discovered.
Surviving Mesothelioma. (2014). Mesothelioma blood test may save lives through earlier diagnosis. [Link]
Recent Posts in the Same Categories
Most Recent in Asbestos & Mesothelioma Studies
- Determining the Exposure Limit for Asbestos
- Funding Needed for Lung Cancer Awareness and Research – How You Can Help
- Quality of Life After Pleurectomy/Decortication vs. Extra Pleural Pneumonectomy
- Phase 1 Clinical Trial For Those With Peritoneal Mesothelioma Underway
- Decade Long Study Reveals Potential for Early Detection in Mesothelioma
Most Recent in Full Archive
Most Recent in Mesothelioma Blood Test
- Metal-based Compound May Reduce Tumor Size in Pleural, Peritoneal Mesothelioma
- Calretinin More Effective Than Mesothelin in Detecting Mesothelioma Early
- New research suggests earlier mesothelioma diagnosis is a possibility
- Gene Expression Ratio Test Predicts Post-Surgery Outcome in Mesothelioma
- Rosetta Genomics Announces Commercial Availability of Its Third MicroRNA-Based Diagnostic Test: miRview(TM) meso